OptimizeRx Expands Exclusive Partnership with Allscripts for Prescription Cost Savings and Real-time Messaging at Point-of-Care
“Our goal at
Allscripts’ industry leading electronic health record (EHR) and ePrescribing (eRx) network totals more than 180,000 physicians across 45,000 ambulatory facilities, 2,500 hospitals and 17,000 post-acute organizations. In 2017, Allscripts achieved an industry-leading milestone of one billion data exchange transactions through its platform – the most in a single year.
OptimizeRx’s growing EHR and eRx network now reaches more than 500,000 healthcare providers (HCPs) in the U.S., making it the healthcare industry’s largest point-of-prescribe network. It delivers real-time access to financial assistance, education, and critical clinical information from pharma companies to HCPs.
“Our long-running relationship with Allscripts, a recognized global leader in healthcare information technology, reflects the unmatched value proposition we offer to our EHR and pharma manufacturer partners,” said
About
Important Cautions Regarding Forward Looking Statements
This press release contains forward-looking statements within the definition of Section 27A of the Securities Act of 1933, as amended and such section 21E of the Securities Act of 1934, amended. These forward-looking statements should not be used to make an investment decision. The words 'estimate,' 'possible' and 'seeking' and similar expressions identify forward-looking statements, which speak only as to the date the statement was made. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
OptimizeRx Contact:
Tel (248) 651-6568 x807
dbaker@optimizerx.com
OptimizeRx Investor Relations:
Tel (949) 432-7557
oprx@cma.team
Source: OptimizeRx Corporation